| 1 |
Nelson LS, Erdman AR, Booze LL, et al. Selective serotonin reuptake inhibitor poisoning: an evidence-based consensus guideline for out-of-hospital management[J]. Clin Toxicol (Phila), 2007, 45 (4): 315-332.
|
| 2 |
Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2003, 27 (1): 85-102.
|
| 3 |
Wood DM, Rajalingam Y, Greene SL, et al. Status epilepticus following intentional overdose of fluvoxamine: a case report with serum fluvoxamine concentration[J]. Clin Toxicol (Phila), 2007, 45 (7): 791.
|
| 4 |
Deshpande K. Isolated fluvoxamine poisoning presenting with hypertonia and seizures: a case report[J]. Crit Care Resusc, 2002, 4 (3): 177-180.
|
| 5 |
Otter J, McIntyre IM, Morhaime J, et al. A fluvoxamine-related fatality: case report with postmortem concentrations[J]. Forensic Sci Int, 2019 (300): e31-e33.
|
| 6 |
Garnier R, Azoyan P, Chataigner D, et al. Acute fluvoxamine poisoning[J]. J Int Med Res, 1993, 21 (4): 197-208.
|
| 7 |
Kan'o T, Kamijo Y, Hattori J, et al. Refractory status epilepticus, circulatory collapse after cardiac arrest, and acute respiratory distress syndrome caused by severe isolated fluvoxamine poisoning: a case report[J]. Acute Med Surg, 2015, 2 (1): 53-55.
|
| 8 |
Kawano T, Kosuge T, Takagi S, et al. First death case of serotonin syndrome in Japan induced by fluvoxamine and tandospirone[J]. Chudoku Kenkyu, 2011, 24 (4): 305-310.
|
| 9 |
Vignali C, Moretti M, Quaiotti J, et al. Distribution of fluvoxamine and identification of the main metabolite in a fatal intoxication[J]. J Anal Toxicol, 2021, 45 (4): e1-e5.
|
| 10 |
Lenzi A, Raffaelli S, Marazziti D. Serotonin syndrome-like symptoms in a patient with obsessive-compulsive disorder, following inappropriate increase in fluvoxamine dosage[J]. Pharmacopsychiatry, 1993, 26 (3): 100-101.
|
| 11 |
Bastani JB, Troester MM, Bastani AJ. Serotonin syndrome and fluvoxamine: a case study[J]. Nebr Med J, 1996, 81 (4): 107-109.
|
| 12 |
Buchberger R, Wagner W. Fluvoxamine: safety profile in extensive post-marketing surveillance[J]. Pharmacopsychiatry, 2002, 35 (3): 101-108.
|
| 13 |
Dell'Osso B, Allen A, Hollander E. Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder[J]. Expert Opin Pharmacother, 2005, 6 (15): 2727-2740.
|